Kirk R. Schultz

Active 1990–2025

110
Papers
18,242
Citations
66
h-index
105
i10-index

Citations

Citations per year for Kirk R. Schultz1991: 1 citations1993: 2 citations1994: 1 citations1995: 1 citations1997: 2 citations1998: 4 citations1999: 1 citations2000: 3 citations2001: 8 citations2002: 6 citations2003: 16 citations2004: 9 citations2005: 12 citations2006: 48 citations2007: 40 citations2008: 82 citations2009: 87 citations2010: 107 citations2011: 112 citations2012: 124 citations2013: 103 citations2014: 110 citations2015: 164 citations2016: 134 citations2017: 147 citations2018: 124 citations2019: 454 citations2020: 605 citations2021: 575 citations2022: 480 citations2023: 316 citations2024: 606 citations2025: 225 citations1992: no citations, so this year is not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,712 citing papers, 25.4% of this breakdownGermany: 489 citing papers, 7.2% of this breakdownUnited Kingdom: 398 citing papers, 5.9% of this breakdownItaly: 374 citing papers, 5.5% of this breakdownFrance: 369 citing papers, 5.5% of this breakdownCanada: 316 citing papers, 4.7% of this breakdownChina: 283 citing papers, 4.2% of this breakdownNetherlands: 277 citing papers, 4.1% of this breakdownSpain: 213 citing papers, 3.2% of this breakdownSwitzerland: 182 citing papers, 2.7% of this breakdownJapan: 175 citing papers, 2.6% of this breakdownAustralia: 172 citing papers, 2.5% of this breakdown
0%25.4%Other 26.5%

Fields

  • Medicine83.5%
  • Biochemistry, Genetics and Molecular Biology8.2%
  • Immunology and Microbiology6.5%
  • Health Professions0.3%
  • Neuroscience0.2%
  • Dentistry0.2%
  • Other1.1%

Topics

  • Hematopoietic Stem Cell Transplantation16.7%
  • Acute Lymphoblastic Leukemia research9.6%
  • Acute Myeloid Leukemia Research6.4%
  • Immune Cell Function and Interaction4.3%
  • T-cell and B-cell Immunology4%
  • Childhood Cancer Survivors' Quality of Life3.9%
  • Other55.1%

Coauthors

All papers

Open in search
  1. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2005 cited by 3,530

  2. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David A. Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrović, Kirk R. Schultz, Gregory A. Yanik, Edmund K. Waller, John E. Levine, James L.M. Ferrara, Bruce R. Blazar, Amelia Langston, John Horan, Leslie S. Kean - Journal of Clinical Oncology 2021 cited by 249

  3. EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

    Authors: , , , , , , , , , , , , , - Bone Marrow Transplantation 2018 cited by 491

  4. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 cited by 419

  5. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Peter Gale, John Koreth, Nelson J. Chao, Mahmoud Aljurf, Brenda Cooper, Mary J. Laughlin, Jack W. Hsu, Peiman Hematti, Leo F. Verdonck, Melhelm M. Solh, Maxim Norkin, Vijay Reddy, Rodrigo Martino, Shahinaz M. Gadalla, Jenna D. Goldberg, Philip L. McCarthy, Josè Antonio Pérez-Simón, Nandita Khera, Ian D. Lewis, Yoshiko Atsuta, Richard F. Olsson, Wael Saber, Edmund K. Waller, Didier Blaise, Joseph A. Pidala, Paul J. Martin, Prakash Satwani, Martin Bornhäuser, Yoshihiro Inamoto, Daniel J. Weisdorf, Mary M. Horowitz, Steven Z. Pavletic - Biology of Blood and Marrow Transplantation 2014 cited by 435

  6. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adriana Balduzzi, on behalf of the I-BFM SCT Study Group, Selim Corbacioglu, on behalf of the EBMT Paediatric Diseases Working Party, Peter Bader - Journal of Clinical Oncology 2020 cited by 329

  7. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2016 cited by 456

  8. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hildegard Greinix, Stefanie Sarantopoulos, Gèrard Socié, Bruce R. Blazar, Joseph Pidala, Carrie L. Kitko, Daniel R. Couriel, Corey Cutler, Kirk R. Schultz, Steven Z. Pavletic, Stephanie J. Lee, Sophie Paczesny - Transplantation and Cellular Therapy 2021 cited by 143

  9. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 363

  10. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2021 cited by 167

  11. Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 255

  12. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Robinson, Michael E. Ward, Bryce B. Reeve, Lisa G. Rider, Howard M. Shulman, Kirk R. Schultz, Daniel Weisdorf, Georgia B. Vogelsang - Biology of Blood and Marrow Transplantation 2006 cited by 565

  13. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2014 cited by 449

  14. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2014 cited by 280

  15. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 250

  16. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nasheed Hossain, Christopher G. Kanakry, Mohamed A. Kharfan‐Dabaja, Nandita Khera, Yener Koç, Hillard M. Lazarus, Jong Wook Lee, Johan Maertens, Rodrigo Martino, Joseph P. McGuirk, Reinhold Munker, Hemant S. Murthy, Ryotaro Nakamura, Sunita Nathan, Taiga Nishihori, Neil Palmisiano, Sagar S. Patel, Joseph Pidala, Rebecca L. Olin, Richard F. Olsson, Betül Oran, Olle Ringdén, David A. Rizzieri, Jacob M. Rowe, Mary Lynn Savoie, Kirk R. Schultz, Sachiko Seo, Brian C. Shaffer, Anurag K. Singh, Melhem Solh, Keith Stockerl‐Goldstein, Leo F. Verdonck, John L. Wagner, Edmund K. Waller, Marcos de Lima, Brenda M. Sandmaier, Mark R. Litzow, Dan Weisdorf, Rizwan Romee, Wael Saber - Blood Advances 2019 cited by 128

  17. NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 cited by 315

  18. Exome Sequencing and the Management of Neurometabolic Disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Oluseye A. Ogunbayo, Bojana Rakić, Jacob Rozmus, Peter C. Ruben, Bryan Sayson, Saikat Santra, Kirk R. Schultz, Kathryn Selby, Paul Shekel, Sandra Sirrs, Cristina Skrypnyk, Andrea Superti‐Furga, Stuart E. Turvey, Margot I. Van Allen, David S. Wishart, Jiang Wu, John K. Wu, Dimitrios Zafeiriou, Leo A. J. Kluijtmans, Ron A. Wevers, Patrice Eydoux, Anna Lehman, Hilary Vallance, Sylvia Stöckler‐Ipsiroglu, Graham Sinclair, Wyeth W. Wasserman, Clara D.M. van Karnebeek - New England Journal of Medicine 2016 cited by 280

  19. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

    Authors: , , , , , , , , , , , , - Blood 2015 cited by 224

  20. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 cited by 96

  21. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bipin N. Savani, Kirk R. Schultz, Sachiko Seo, Takanori Teshima, Marjolein van der Poel, Leo F. Verdonck, Daniel Weisdorf, Baldeep Wirk, Jean A. Yared, Jeffrey Schriber, Richard E. Champlin, Stefan O. Ciurea - Transplantation and Cellular Therapy 2022 cited by 32

  22. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2023 cited by 39

  23. Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2006 cited by 484

  24. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report

    Authors: , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 cited by 232